Vizsgálati helyszín
Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
Ankara, 06200, TörökországMég nincs intézményhez kötve
- 13futó vizsgálat
- 4lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 17 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis9 vizsgálat
- 2. fázis4 vizsgálat
- 1. fázis1 vizsgálat
- 1/2. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz7 vizsgálat
- Toboroz6 vizsgálat
- Lezárult3 vizsgálat
- Visszavonták1 vizsgálat
- Fő szponzor
- Janssen Research & Development, LLC11 vizsgálat
- BioNTech SE2 vizsgálat
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital1 vizsgálat
- Gazi University1 vizsgálat
- OncoVerity, Inc.1 vizsgálat
- és még 1
Futó vizsgálatok
Toboroz
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
NCT06449209· 2. fázis· BioNTech SE· Forrás
Fut, nem toboroz
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
NCT06161441· 2. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
NCT05142189· 1. fázis· BioNTech SE· Forrás
Fut, nem toboroz
A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
NCT04023526· 2. fázis· OncoVerity, Inc.· Forrás
Fut, nem toboroz
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
NCT03473743· 1/2. fázis· Janssen Research & Development, LLC· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek